LYTENAVABlack Triangle Icon

(bevacizumab gamma) 25 mg/mL solution for injection

What you need to know about LYTENAVATM for the treatment of neovascular (wet) age-related macular degeneration (nAMD)

Your guide to LYTENAVATM

Watch and listen to the audiovisual version of the guide below

Lytenava (bevacizumab gamma) patient guide Play Video Icon

This guide is intended to offer you useful information to help you understand your condition and know what to expect with LYTENAVATM treatment

Download transcript
Lytenava (bevacizumab gamma) patient guide
Download a digital version of the guide
Download PDF

Please report side effects to the MHRA through the Yellow Card scheme. You can report via:

Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.

Black Triangle IconThis medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.